A Phase 1, Open Label, Fixed-sequence Study to Evaluate the Effect of BAY1841788 (ODM-201) on Drug Transporters Using Rosuvastatin as Probe Substrate and to Assess Pharmacokinetics and Safety of BAY1841788 in Female and Male Volunteers

Trial Profile

A Phase 1, Open Label, Fixed-sequence Study to Evaluate the Effect of BAY1841788 (ODM-201) on Drug Transporters Using Rosuvastatin as Probe Substrate and to Assess Pharmacokinetics and Safety of BAY1841788 in Female and Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs Darolutamide (Primary)
  • Indications Prostate cancer
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 07 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 16 May 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016.
    • 16 May 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top